TABLE 1.
Pharmacokinetic parameters for a group of HIV-seropositive receiving foscarnet orally and intravenouslya
| Group and day | Cmax (μM) | Tmax (h) | t1/2z (h) | AUC0–∞ (μM · h) | F (%) | Accumulation ratio | Urinary excretion of foscarnet over 24 h (% of dose) |
|---|---|---|---|---|---|---|---|
| 90 mg/kg QD | |||||||
| Day 1 (n = 6) | 46.4 ± 10.8 | 1.6 ± 0.7 | 6.7 ± 2.6 | 300 ± 60 | 9.1 ± 2.2 | 7.7 ± 3.0 | |
| Day 8 (n = 6) | 86.2 ± 35.8b | 1.4 ± 0.6 | 7.6 ± 1.2 | 646 ± 243c | 2.1 ± 1.1 | 16.6 ± 7.4b | |
| 90 mg/kg BIDd | |||||||
| Day 1 (n = 6) | 45.7 ± 6.9 | 2.0 ± 0.3 | 4.0 ± 1.3 | 298 ± 47 | 9.5 ± 1.7 | 8.7 ± 2.1 | |
| Day 8 (n = 4e) | 78.7 ± 35.2 | 1.8 ± 0.7 | 5.7 ± 2.7 | 688 ± 223b | 1.8 ± 0.4 | 11.3 ± 2.8 | |
| 180 mg/kg QD | |||||||
| Day 1 (n = 3) | 64.9 ± 31.7 | 1.7 ± 0.3 | 5.4 ± 0.4 | 494 ± 188 | 7.6 ± 3.7 | 6.0 ± 2.7 | |
| Day 8 (n = 3) | 86.4 ± 25.0 | 2.0 ± 1.0 | 5.6 ± 0.4 | 826 ± 195 | 1.7 ± 0.7 | 9.9 ± 2.5 | |
| 90 mg/kg intravenously (n = 13e) | 887.3 ± 102.7 | 2.0 ± 0.0 | 5.7 ± 0.2 | 3,308 ± 496 | 95.3 ± 4.9 |
a
Tmax, time to Cmax; F, bioavailability; the other abbreviations are defined in the text. Values are means ± standard deviations.
b
P < 0.05 versus day 1.
c
P < 0.01 versus day 1.
d
Data are for first dose of BID dosing schedule.
e
Excludes data for two patients who withdrew from the study.